About

Harsher Singh was appointed CEO of Jubilant Radiopharma in April 2024. With a proven track record in the biopharmaceutical industry, Harsher brings valuable expertise to the radiopharmaceutical division. Prior to joining the Jubilant team, Harsher was Senior Vice President at Amneal Biosciences where he led the Biosimilar, Biologic and Injectable business lines and served as Amneal's strategic leader for AvKare Distribution Business. Prior to Amneal, he worked for American Regent, Inc. and McKinsey & Company. Harsher holds an MBA from Northwestern University – Kellogg School of Management, and a BSc in Economics from the London School of Economics and Political Science.

Appointed Senior Vice President and Chief Medical Officer of Jubilant Radiopharma and Jubilant Threapeutics in 2024, bringing over 32 years of experience in medicine, cardiology, research, imaging and innovation in academic and pharmaceutical medicine to global healthcare.

Previously, Melda was Global Medical and Regulatory Affairs Executive Senior Director at Bracco Diagnostics and Research Professor at Saint Louis University Hospital Cardiology. She served as a key opinion leader in healthcare globally.

Krishna Khaitan is a seasoned finance leader with over 30 years of global experience in the pharmaceutical and manufacturing industries. As head of Finance at Jubilant Radiopharma, Krishna leads the company’s financial strategy, planning, and performance initiatives, driving operational excellence and long-term value creation.

Before joining Jubilant in 2022, Krishna served as Chief Financial Officer at AV Group, where he played a pivotal role in improving financial profitability and supporting strategic growth. He is a Chartered Accountant and holds both an MBA and a Bachelor of Commerce degree.

Krishna is widely recognized for his empathetic leadership style and commitment to human-centric management, fostering trust and collaboration across teams. His deep expertise in financial management and business transformation continues to shape Jubilant Radiopharma’s success in a dynamic healthcare landscape.